Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Stergios A. Pοlyzos, Јannis Kountouras, Christos S. Mantzoros
Metabolism (2018) Vol. 92, pp. 82-97
Closed Access | Times Cited: 937

Showing 1-25 of 937 citing articles:

Non-alcoholic fatty liver disease
Elizabeth E. Powell, Vincent Wai‐Sun Wong, Mary E. Rinella
The Lancet (2021) Vol. 397, Iss. 10290, pp. 2212-2224
Closed Access | Times Cited: 1778
Inflammation in obesity, diabetes, and related disorders
Theresa V. Rohm, Daniel T. Meier, Jerrold M. Olefsky, et al.
Immunity (2022) Vol. 55, Iss. 1, pp. 31-55
Open Access | Times Cited: 1080
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes
Amélio F. Godoy‐Matos, Wellington S. Silva Júnior, Cynthia Melissa Valério
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 477
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, et al.
Metabolism (2020) Vol. 111, pp. 154170-154170
Open Access | Times Cited: 437
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
Fasiha Kanwal, Jay H. Shubrook, Leon A. Adams, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1657-1669
Open Access | Times Cited: 366
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
Jingxuan Quek, Kai En Chan, Zhen Yu Wong, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 1, pp. 20-30
Closed Access | Times Cited: 326
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome
Stavroula Α. Paschou, Stergios A. Pοlyzos, Panagiotis Anagnostis, et al.
Endocrine (2019) Vol. 67, Iss. 1, pp. 1-8
Closed Access | Times Cited: 210
Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease
Dimitrios A. Koutoukidis, Nerys M. Astbury, Kate Tudor, et al.
JAMA Internal Medicine (2019) Vol. 179, Iss. 9, pp. 1262-1262
Open Access | Times Cited: 190
NAFLD and liver transplantation: Disease burden, current management and future challenges
Patrizia Burra, Chiara Becchetti, Giacomo Germani
JHEP Reports (2020) Vol. 2, Iss. 6, pp. 100192-100192
Open Access | Times Cited: 177
Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990–2017: a population-based observational study
Xiao-Jun Ge, Limei Zheng, Mei Wang, et al.
BMJ Open (2020) Vol. 10, Iss. 8, pp. e036663-e036663
Open Access | Times Cited: 164
Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
Evangelia Makri, A. Goulas, Stergios A. Pοlyzos
Archives of Medical Research (2020) Vol. 52, Iss. 1, pp. 25-37
Closed Access | Times Cited: 163
Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
Leen Heyens, Dana Busschots, Ger H. Koek, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 161
Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations
Ramesh Kumar, Rajeev Nayan Priyadarshi, Utpal Anand
Journal of Clinical and Translational Hepatology (2019) Vol. X, Iss. X, pp. 1-11
Open Access | Times Cited: 153
Immunological mechanisms and therapeutic targets of fatty liver diseases
Hua Wang, Wajahat Z. Mehal, Laura E. Nagy, et al.
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 1, pp. 73-91
Open Access | Times Cited: 152
The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis
Laura Haigh, Colette Kirk, Khalil El Gendy, et al.
Clinical Nutrition (2022) Vol. 41, Iss. 9, pp. 1913-1931
Open Access | Times Cited: 114
The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease
Sylwia Ziółkowska, Agata Binienda, Maciej Jabłkowski, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 11128-11128
Open Access | Times Cited: 113
Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease
Raghu Ramanathan, Ahmad H. Ali, Jamal A. Ibdah
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7280-7280
Open Access | Times Cited: 98
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Θεόδωρος Ανδρουτσάκος, Narjes Nasiri‐Ansari, Athanasios‐Dimitrios Bakasis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3107-3107
Open Access | Times Cited: 93
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors
Emir Muzurović, Carol Chiung‐Hui Peng, Matthew J. Belanger, et al.
Hypertension (2022) Vol. 79, Iss. 7, pp. 1319-1326
Closed Access | Times Cited: 84
Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
Narjes Nasiri‐Ansari, Θεόδωρος Ανδρουτσάκος, Christina‐Maria Flessa, et al.
Cells (2022) Vol. 11, Iss. 16, pp. 2511-2511
Open Access | Times Cited: 75
Resmetirom: An Orally Administered, Small-molecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
Gres Karim, Meena B. Bansal
touchREVIEWS in Endocrinology (2023) Vol. 19, Iss. 1, pp. 60-60
Open Access | Times Cited: 66
Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation
Neda Yahoo, Michael Dudek, Percy A. Knolle, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 538-551
Open Access | Times Cited: 61
METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy
Yasi Pan, Huarong Chen, Xiang Zhang, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 8, pp. 101144-101144
Open Access | Times Cited: 60
Obesity and diabetes
Chrysoula Boutari, Antea DeMarsilis, Christos S. Mantzoros
Diabetes Research and Clinical Practice (2023) Vol. 202, pp. 110773-110773
Closed Access | Times Cited: 56
Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis
Federico Ravaioli, Elton Dajti, Alessandro Mantovani, et al.
Gut (2023) Vol. 72, Iss. 7, pp. 1399-1409
Closed Access | Times Cited: 49
Page 1 - Next Page

Scroll to top